Patent Grant
12344639
The invention is related to chimeric gas vesicles (CGVs) and uses thereof.
Gas vesicles are intracellular, protein-coated and hollow organelles found in cyanobacteria, soil bacteria and halophilic archaea. They are permeable to ambient gases by passive diffusion and provide buoyancy which enables bacteria cells to adjust their vertical position in aqueous environments for access of oxygen and light.
Gas vesicles are cylindrical-shaped with conical-ends nanostructures of 40 to 250 nm in width and 50 to 1000 nm in length. The discrete protein nanoparticles with permeability to ambient gas provides great potential for bioengineering for a variety of applications. Development of biological imaging under resonance and expansion of biomass production counting on its positive increase of buoyancy has been described in a variety of prior arts. Besides, the nano-scale bio-particles are desirable vehicles for vaccines.
Disclosed in Pat. WO1990010071A1 are recombinant cells and a recombinant vector for gas vesicle protein expression in E. coli and improvement of floatation properties of the transformed cells. Bacillus thuringiensis israelensis (Bti) is a group of bacteria which can be used as biological control agents for larvae stages of certain dipterans. When transformed with gas vesicle genes, the tendency of Bti to settle in water is reduced and its larvicidal activity becomes more persistent. Other hosts overcome sedimentation problems in bio-reactors with incorporation of gas vesicle genes, which improves bio-degradation of organic wastes or medical/agricultural products.
In Pat. WO2018043716A1, Mizushima and Watanabe published a method for introducing gas vesicle genes including gvpA and gvpC into eukaryotic cells for gas vesicle protein expression. The gvpA and gvpC genes are derived from cyanobacteria and featured with optimized codons for mammalian expression. A transposon vector serves as the vehicle of gvpA and gvpC genes for introduction of genes into mammalian cells. The method disclosed in this prior art also provides a kit for establishing a stable clone or a transgenic animal for constant production of gas vesicles.
In US Pat. US20140234904A1, Stephen and Levi disclosed methods for harvesting photosynthetic unicellular organisms and the formation of gas vesicles in the photosynthetic unicellular organisms. The self-assembling gas vesicle proteins form conical filaments which are capable of blocking water molecules but allow the diffusion of gas. Overexpression of the gas vesicle increases positive buoyancy of the photosynthetic unicellular organisms and allows for harvesting without the need for centrifugation, filtration, or chemical flocculation.
Shapiro et al (Science 27 Sep. 2019: Vol. 365, Issue 6460, pp. 1469-1475) described a protocol for gas vesicle isolation and functionalization. The nanostructures of gas vesicles are modified with moieties for targeting and fluorescence, and using ultrasound and magnetic resonance for imaging. It takes 3 to 8 days for preparation of these genetically encodable nanostructures, and the nanostructures enable multi-modal and noninvasive biological imaging featuring high sensitivity and potential for molecular targeting.
In Pat. WO2021041934A1, Jin et al disclosed an engineered protease sensitive gas vesicle. The engineered protease sensitive gas vesicle comprises a GvpA or GvpB protein and an engineered GvpC protein. Protease recognition sites are inserted within a central portion of the GvpC or attached to the N or C-terminus of the GvpC. The engineered gas vesicles exhibit an ultrasound response with baseline nonlinearity to collapse. Proteases bind to the recognition sites and result in cleavage thereof. Subsequently the engineered gas vesicles collapse following the cleavage and detection of the collapses is for screening engineered protease sensitive gas vesicles. The method enables reduction of collapse pressure profile, protease degradation, and sufficient protein yield is obtained with improvement of engineered gas vesicle expression in host cells. Also, ultrasound applied to obtain detection and sensing presents an enhanced nonlinear behavior.
In US Pat. U.S. Pat. No. 5,824,309, DasSarma et al disclosed a method for producing protein vaccines by utilizing recombinant gas vesicles. Foreign epitopes derived from pathogens are inserted into gvpA or gvpC for antigen presenting to elicit immunogenicity of subjects upon administration. In absence of an adjuvant, vaccination with the recombinant gas vesicles result in long-lasting immunoglobulin IgG or IgM responses. Archaeon cells Halobacterium halobium are cultured as a host for the engineered gas vesicle preparation.
Majority of GV research was conducted in halobacteria, cyanobacteria and Priestia megaterium (previously known as Bacillus megaterium).
In cyanobacteria and halobacteria, the lipid-free, rigid proteinaceous membrane consists exclusively of proteins: the major hydrophobic 70 to 85 amino acid (AA) GvpA protein, which forms GV ribbed basic structure, and a minor constituent, hydrophilic 200- to 450-AA GvpC, located on the GV outer surface as shown in
Besides the major GV structural protein GvpA and minor GV scaffold structural protein GvpC, five accessory GV proteins: GvpJ, GvpM, GvpF, GvpG, GvpL are detected by immunoblotting in the GV of halobacteria as indicated in
Gas vesicle protein A (GvpA) is the major structural protein of gas vesicles and constitutes the majority (97%) of the gas vesicle wall. The wall is 2 nm thick and consists of a single layer of GvpA. GvpA forms 4.6 nm ‘ribs’ that run nearly perpendicular to the long axis of the gas vesicle. As demonstrated in
GvpA protein encoded by gvpA genes from several dozens of different microorganisms are sequenced and identified. The GvpA protein sequences are highly homologous, especially in the α-helix, β-sheet, β-sheet and α-helix core sequence as indicated in
Multiple identical copies of gvpA gene are found in some cyanobacteria, two copies of slightly different gvpA gene are found on two gyp operons located on its chromosome and plasmid separately in halobacteria (c-vac and p-vac) and on a 14 gene gyp operon in P. megaterium (gvpA and gvpB).
It has been long recognized by the research field that there is only one kind of rib protein GvpA in each gas vesicle. In Halobacterium salinarum, c-vac and p-vac are located on different gene clusters at chromosome or plasmid respectively. The expression of c-vac and p-vac is under control by different mechanisms and thus the gas vesicle formed with either GvpA from c-vac or GvpA from p-vac at one time, not both. In P. megaterium, gvpA and gvpB are on the same 14-gene gyp operon. Only gvpB is needed to form the gas vesicle and the role of gvpA is unclear.
Attempts are made to modify GvpA by insertion of heterologous peptide sequence into the N-terminal, C-terminal, or core sequence of GvpA. However, the rigid nature of GvpA protein limits the capacity of GvpA modification. DasSarma's group revealed that in-frame attachment of more than 5 heterologous amino acids to the C-terminal of GvpA in H. salinarum result in its incapability of forming gas vesicles. Other insertion attempts at N-terminal, and core sequence of GvpA are failed as well. This limits the use of gas vesicles in various applications such as vaccines, biomarkers, etc.
GvpC is a minor scaffold structural protein and found on the gas vesicle surface in cyanobacteria and halophilic archaea. It accounts for 2.9% of total protein content of gas vesicles from Anabaena flos-aquae and it can be stripped from gas vesicles by detergent or the change of salt concentration. It is a scaffold protein which stabilizes gas vesicles through protein-protein interaction with GvpA. Attachment of heterologous peptides to GvpC can be up to 398 amino acids long in H. salinarum, which makes GvpC more applicable in bioengineering. The gas vesicles with the modification of GvpC are called gas vesicle nanoparticles (GVNPs).
Nonetheless, attachment of GvpC to gas vesicles is not stable and the ratio of GvpC/GvpA or GvpC/GV in gas vesicles is difficult to maintain constant in practice. For instance, the GVNP produced by halobacteria could only maintain stability in a high-salt environment. In a low-salt environment, GVNPs tend to break down its structure and GvpC detaches from the nanoparticles. Instability of GVNP and disassociation of GvpC from GVNP undermines the reliability of GVNPs as an antigen-presenting vehicle or imaging biomarker particles for ultrasound and MRI exam.
In another aspect, the production cycle of gas vesicles in halobacteria is 3 to 4 weeks long and time-consuming, therefore the GV/GVNP production cost in halobacteria is way higher than using the E. coli expression system. Also there is lack of an efficient vector/host system for GV expression and production in halobacteria.
Thus, a new form of genetically engineered chimeric gas vesicle (CGV) is desired to overcome these limitations.
In the gas vesicle research field, it is widely believed that only one protein, GvpA, forms the rib of the gas vesicle. In other words, in a given gas vesicle, there is only one kind of rib protein such as GvpA from cyanobacteria, halobacteria and soil bacteria, or its homolog GvpB from P. megaterium. In the present invention, a chimeric gas vesicle (CGV) involving two or more kinds of rib proteins is disclosed.
The advantages of the chimeric gas vesicles (CGVs) of the present invention over traditional GVs and GVNPs are numerous. For example, previous attempts of direct genetic modification of GvpA in GVs are unsuccessful due to rigidity of GvpA in the GVs, and only a limited number of heterologous peptides can be inserted without the destruction of the GV. The CGV disclosed in the present invention overcomes these limitations and makes the gas vesicle more versatile for various applications. In halobacteria, the genetically modified GvpC of GVNP attaches to GV via protein-protein interaction, which is vulnerable to thermohaline fluctuations and makes GvpC easy to fall off from GVNP. In the present invention, the heterologous peptide inserted in the CGV is covalently fused within the rib protein, which eliminates the fall-off problem of the heterologous peptide present on the CGV. Further, the process for making the CGV can be accomplished within a very short time period, which drastically reduces the production cycle time compared to the time required to make GVNPs in halobacteria or GVs in cyanobacteria. The CGVs are more stable than any other GVs previously described. In other words, the CGVs of the present invention have a higher “critical collapse pressure” than the traditional GVs. In some examples, the CGVs are stable at room temperature for at least one month and at 4° C. for at least six months without any degradation.
In the gas vesicle research field, as shown in
In one aspect, the present invention provides a chimeric gas vesicle comprising at least two Gyp rib proteins, wherein the rib protein is selected from a group consisting of a major rib protein and a minor rib protein, and wherein the major rib protein differentiates from the minor rib protein in that the major rib protein is capable of forming a gas vesicle independently. Preferably, as shown in
In exemplary embodiments, the at least two Gyp rib protein can be two major rib proteins, two minor rib proteins or a combination of one major rib protein and one minor rib protein. Preferably, the minor rib protein forms a complete CGV when the major rib protein is present, and under such circumstances the CGV is more stabilized.
In various embodiments, the major rib protein and the minor rib protein constitute at least 90% of the chimeric gas vesicle by dry weight.
In one or various embodiments, the minor rib protein comprises a core sequence and a heterologous peptide inserted in frame at C-terminus or N-terminus of the core sequence, wherein the core sequence is characterized by a protein structure comprising a first alpha helix, a first beta sheet at C-terminus of the first alpha helix; a second beta sheet at C-terminus of the first beta sheet; and a second alpha helix at C-terminus of the second beta sheet.
In preferred embodiments, the core sequence is selected from a group consisting of a GvpA core sequence and a GvpB core sequence.
In various embodiments, wherein the first alpha helix comprises an amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the first beta sheet comprises an amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17 or SEQ ID NO: 18, the second beta sheet comprises an amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21, and the second alpha helix comprises an amino acid sequence of SEQ ID NO: 22, SEQ ID NO: 23 or SEQ ID NO: 24. Preferably, for SEQ ID NO: 22, SEQ ID NO: 23 or SEQ ID NO: 24, the X residue is Ala or Glu, and for SEQ ID NO: 22, SEQ ID NO: 23 or SEQ ID NO: 24, the Z residue is Val or Ile.
To be specific, the core sequence is a hydrophobic region of GvpA protein or GvpB protein. As illustrated in
In preferred embodiments, the GvpA protein has an amino acid sequence of SEQ ID NO: 1, and the GvpB protein has an amino acid sequence of SEQ ID NO: 2.
More specifically, the core sequence comprises 9th amino acid (Serine) to the 61st amino acid (Valine) of a GvpA protein or a GvpB protein from P. megaterium but not limited by this. In addition, all gas vesicle rib proteins carry the core sequence. Moreover, any homologs of GvpA protein or GvpB protein from cyanobacteria, halobacteria or soil bacteria, or any protein sequence homologous to the core sequence, can be genetically modified and play the role as the minor rib protein.
It should be noted that the secondary structures as mentioned above are predicted by Jpred 4, an online protein secondary structure prediction program. In
Illustrated in
In other embodiments, the heterologous peptide is at least 6 amino acid long, and the heterologous peptide is derived from a human designed peptide sequence, a ligand, a hormone, a cytokine, a receptor, a paratope of antibody, a toxic protein, or a fluorescent protein.
In preferred embodiments, the major rib protein is a GvpB protein, and the minor rib protein is a core sequence with a heterologous peptide, wherein the heterologous peptide has at least 6 amino acids and is inserted in frame at C-terminus or at N-terminus of the core sequence.
Preferably, the core sequence comprises a truncated rib protein keeping the 1st amino acid (Methionine) to the 61st amino acid (Valine) of GvpA protein or GvpB protein from P. megaterium.
Exemplarily, the heterologous peptide of 6 to 56 amino acids or longer can be inserted at C-terminus of the core sequence, and the core sequence is a truncated form of the Gyp rib protein. The truncated Gyp rib protein and the heterologous peptide together forms the minor rib protein which carries a foreign peptide and results in a variety of applications in the biotech field. However, longer heterologous peptide leads to less stability of CGV and reduces the yield of CGV production.
In some embodiments, the heterologous peptide can be derived from two or more heterologous proteins as well. For example, 20-AA from protein A and 25-AA from protein B form a 45-AA heterologous peptide for the insertion to form the minor rib protein. Preferably, the heterologous peptides are derived from the protein sequence of pathogens, variable regions of antibodies, hormones, cytokines and ligands.
In various embodiments, the CGV is expressed in and purified from E. coli.
In one or various embodiments, the chimeric gas vesicle further comprises an assembly protein, and the assembly protein comprises a GvpP protein, a GvpQ protein or a combination thereof. The assembly protein is derived from P. megaterium. These proteins promote or accelerate or stabilize the formation of the CGV. The minor rib proteins are more evenly distributed on the CGV's surface with the presence of GvpP and GvpQ proteins. CGVs formed with the assistance of GvpP and GvpQ are more stable than CGVs without the assistance of GvpP and GvpQ.
In one particular embodiment, the GvpP protein has an amino acid sequence of SEQ ID NO: 3, and the GvpQ protein has an amino acid sequence of SEQ ID NO: 4.
In preferred embodiments, the CGV further comprises at least one accessory protein selected from a group consisting of a GvpR, a GvpN, a GvpF, a GvpG, a GvpL, a GvpS, a GvpK, a GvpJ, a GvpT and a GvpU.
By “chimeric gas vesicles (CGVs)” it means the gas vesicles which constitute with at least two kinds of Gyp rib proteins with different protein sequences. That is in contrast to all the gas vesicles described in previous publications which involve only one major rib protein, GvpA.
By “rib protein” it means the gas vesicle protein which forms the “rib” of GV and CGV. Once a gas vesicle forms, the rib protein can't be removed from a gas vesicle without the destruction of the gas vesicle. The gas vesicle rib protein(s) form ˜4.6-nm ‘ribs’ that stack in array and run nearly perpendicular to the long axis of the gas vesicle and constitute the majority (97%) of the gas vesicle wall. The wall is 2-nm thick and consists of a single layer of the rib protein (
By “major rib protein” it means the GvpA protein in cyanobacteria, halobacteria, and soil bacteria, and GvpB in P. megaterium, or any Gyp proteins homologous to and functionally equivalent to the GvpA protein, which forms the rib of the gas vesicle. The gas vesicle major rib protein is a rib protein with the “core sequence”. Combining with a trace amount of Gyp accessory structure proteins (GvpF, GvpG, GvpJ, GvpK, GvpL, GvpS), it forms complete gas vesicles. It is sufficient to form gas vesicles without the involvement of other rib proteins. Once GV forms, the major rib protein cannot be removed from GV without GV destruction. The gas vesicle major rib protein constitutes 20 to 99.9% of total protein in the GV. It has been referred to as the major structure protein, the major constituent protein, the rib protein, etc.
By “minor rib protein” it means a rib protein with the “core sequence”. It forms a complete gas vesicle only when another kind of rib protein is present. Most of the time the other kind of rib protein is a gas vesicle major rib protein, but it could be another gas vesicle minor rib protein with a different protein sequence. Once CGV forms, the minor rib protein cannot be removed from CGV without CGV destruction. The gas vesicle minor rib protein constitutes 3 to 80% of total protein in the CGV.
The native rib protein is a gas vesicle rib protein, GvpA or its homolog, found in nature. The truncated rib protein is a native gas vesicle rib protein with part of its amino acid sequence removed. The recombinant rib protein is a gas vesicle rib protein, either native or truncated, inserted in frame with a heterologous peptide at C-terminus, N-terminus or in the middle.
By “core sequence” it means the hydrophobic region of GvpA and its homologs which is a tertiary structure consisting of four secondary structures: α-helix, β-sheet, β-sheet, α-helix as indicated in
In another aspect, the present invention discloses a protein expression system for expression of the chimeric gas vesicle, wherein the protein expression system comprises a first polynucleotide fragment encoding one of the Gyp rib proteins and a second polynucleotide fragment encoding the other one of the Gyp rib proteins. The protein expression system can be a DNA-based protein expression system or an RNA-based protein expression system.
In various embodiments, the first polynucleotide fragment encoding the major rib protein; and a second polynucleotide fragment encoding the minor rib protein, wherein the second polynucleotide fragment comprises a core polynucleotide encoding a core sequence; and a heterologous polynucleotide fragment encoding a heterologous peptide.
In preferred embodiments, the core sequence is characterized by a protein tertiary structure comprising a first alpha helix; a first beta sheet at C-terminus of the first alpha helix; a second beta sheet at C-terminus of the first beta sheet; and a second alpha helix at C-terminus of the second beta sheet. Preferably, the core sequence is selected from a group consisting of a GvpA core sequence and a GvpB core sequence.
In particular, the core sequence is a hydrophobic region of GvpA protein or GvpB protein as illustrated in
In one preferred embodiment, the first polynucleotide fragment has a nucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 6.
In various embodiments, the heterologous peptide is at least 6 amino acids long, wherein the heterologous peptide is derived from a native protein sequence selected from a group consisting of a ligand, a hormone, a cytokine, a receptor, a paratope of antibody, a toxic protein and a fluorescent protein, or a human designed peptide sequence.
In some embodiments, the protein expression system further comprises an assembly polynucleotide fragment encoding an assembly protein, wherein the assembly protein comprises a GvpP protein, a GvpQ protein or a combination thereof. With presence of the assembly proteins, the minor rib proteins are more evenly distributed on the CGV's surface. While in absence of GvpP or GvpQ protein, CGVs demonstrate less stability and tend to assemble inappropriately or produce less amount than CGVs with the assistance of the assembly protein.
In certain embodiments, the assembly polynucleotide fragment is derived from P. megaterium gvpP, gvpQ or a combination thereof. Preferably, the assembly polynucleotide fragment has a nucleotide sequence of SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.
In some embodiments, the protein expression system further comprises an accessory polynucleotide fragment encoding at least one accessory protein, wherein the accessory protein is selected from a group consisting of a GvpR, a GvpN, a GvpF, a GvpG, a GvpL, a GvpS, a GvpK, a GvpJ, a GvpT and a GvpU. In certain embodiments, the accessory polynucleotide fragment is derived from P. megaterium gvpR, gvpN, gvpF, gvpG, gvpL, gvpS, gvpK, gvpJ, gvpT, gvpU or a combination thereof. Preferably, the accessory polynucleotide fragment has a nucleotide sequence of SEQ ID NO: 10.
In some embodiments, the protein expression system can be induced in a host to express the Gyp rib proteins, wherein the host comprises an archaeon cell, a prokaryotic cell, or a eukaryotic cell. Preferably, the archaeon cell is H. salinarum; the prokaryotic cell is E. coli; the eukaryotic cells are a mammalian cell, a yeast cell or an insect cell. More preferably, the host is E. coli.
As illustrated in
In some embodiments, to minimize the influence brought by longer heterologous peptide, numbers of amino acid deletion of the Gyp rib protein shall be considered. Without interruption of CGVs assembly and formation, a maximal deletion at GvpA C-terminus is 25-AA, while the maximal deletion at GvpB C-terminus is 27-AA. In an exemplary embodiment, maximal GvpA truncation and maximal heterologous peptide insertion were determined. As shown in TABLE 1, 25 amino acids can be removed from GvpA of P. megaterium without the destruction of CGV, and at least 56-AA heterologous peptide can be inserted into the truncated GvpA at C-terminus without the destruction of CGV. Besides, it can be inferred from TABLE 1 that less deletion of rib protein GvpA or GvpB at C-terminus is applicable when shorter heterologous peptide insertion is required.
In some other embodiments, the protein expression system can be carried out by two or more different expression vectors for subsequent CGVs expression in a host. In one exemplary embodiment, a polynucleotide fragment encoding GvpA, GvpP and GvpQ is inserted in a first vector, and another polynucleotide fragment encoding GvpB, GvpR, GvpN, GvpF, GvpG, GvpL, GvpS, GvpK, GvpJ, GvpT and GvpU is inserted in a second vector. The first vector and the second vector are co-transformed into a host for production of the CGVs. Preferably, the vectors are derived from plasmid pST39 and plasmid pLysS for E. coli host.
By “vector” it means a nucleic acid molecule comprising gene-expressing elements and elements for genetic engineering so as to carry genes of interest into a selected host for specific biological functions such as protein expression or amplifying the copy number of genes of interest.
In other preferred embodiments, as illustrated in
As illustrated in
Practically, an operator or a promoter is required upstream the gvpAPQ polynucleotide fragment, the gvpBPQ polynucleotide fragment, the gvpBRNFGLSKJTU polynucleotide fragment, the gvpAPQBRNFGLSKJTU polynucleotide fragment and the gypBPQBRNFGLSKJTU polynucleotide fragment so that the gyp operon system can be operated for synthesis of proteins required for CGV assembly upon induction of isopropylthiogalactoside (IPTG), lactose, methyl-β-D-thiogalactoside, phenyl-β-D-galactose or ortho-nitrophenyl-β-galactoside (ONPG), but not limited by this.
In one preferred embodiment, the gvpAPQBRNFGLSKJTU polynucleotide fragment has a 7053-bp DNA sequence encoding GvpA, GvpP, GvpQ, GvpB, GvpR, GvpN, GvpF, GvpG, GvpL, GvpS, GvpK, GvpJ, GvpT and GvpU proteins and can be inserted into an appropriate expression vector for CGVs protein expression; preferably the gvpAPQBRNFGLSKJTU polynucleotide fragment has a nucleotide sequence of SEQ ID NO: 11.
In one another aspect, the present invention as shown in
(Step S1) Construction of plasmid: a plasmid is constructed by inserting a DNA sequence encoding a heterologous peptide having 6 to 56 amino acids or above in-frame at the C-terminus and/or N-terminus of the genetically engineered GvpA or GvpB protein in a recombinant gyp operon derived from P. megaterium by PCR and Gibson Assembly.
(Step S2) Transformation of plasmid: the constructed plasmid is transformed into E. coli or other suitable bacteria hosts capable of expression and production of CGV.
(Step S3) Induction: the transformant is grown in a proper environment to an optimal condition for inducing protein expression. The transformant is stimulated with IPTG (Isopropyl β-d-1-thiogalactopyranoside) or other inducers for the expression of the CGV.
(Step S4) Purification and quantification of the CGV.
To verify the sequence of the recombinant operon, the method further comprises a step of:
(Step S1.1) Sequence validation: The plasmid sequence with desired insertion is confirmed by DNA sequencing after step S1.
In some embodiments, the step S1 comprises constructing a CGV expression plasmid by inserting a DNA sequence encoding the minor rib protein into a gyp operon vector by PCR and Gibson Assembly, wherein the minor rib protein has a heterologous peptide at least 6 amino acids (AAs) inserted in frame as a recombinant.
In yet one another aspect, the present invention as shown in
In a certain embodiment, CGV-Covid-19 is administrated on the subject in need via intranasal administration, wherein a 17-AA heterologous peptide derived from S-protein of Covid-19 virus is inserted at C-terminus of the core sequence so that the CGV presents an epitope derived from SARS-CoV-2 (Covid-19) spike protein. Enzyme-linked immunosorbent assay (ELISA) is applied to measure elicitation of the immune responses by the CGV-Covid-19 vaccine, but the measure for detection is not limited by this. The subject in need includes human, mice, canine, porcine, chimpanzee or other mammal.
The CGVs of the invention may be used as vaccines for infectious diseases, therapeutic vaccines for cancer and other diseases. They can be therapeutic agents (such as carrying hormones, cytokines, ligands, or part of variable regions of antibodies) for cancer, metabolic diseases, and other diseases. They can also function as non-invasive contrast agents for ultrasound, MRI and other imaging technologies. In short, a wide variety of applications are possible with the CGVs used as a nanoparticle.
Construction and Confirmation of Plasmid
Any effective E. coli plasmid/host expression system can be used, such as pBB322 derived plasmids/BL21 E. coli strain (New England Biolab), pET28 plasmid/BL21(A1) E. coli strain (Thermo Fisher) or pST39 plasmid/Rosetta E. coli strain (Millipore Sigma).
The plasmid was digested with restriction enzyme/enzymes or PCR with particular primers to generate the corresponding DNA fragment. The proper DNA primers encoding a peptide of interest were designed and ordered from any commercial primer vendors by one of ordinary skill in the art.
The DNA fragment encoding heterologous truncated GvpA protein or GvpB protein with a peptide of interest, and a DNA fragment carrying the rest of 13 gyp genes: gvpPQBRNFGLSKJTU from P. megaterium were amplified by PCR with the proper DNA primers. The fragments were subsequently ligated by Gibson Assembly (Thermo Fisher). The Gibson Assembly mixture was transformed into proper E. coli competent cells and transformants were analyzed and sequenced by one of ordinary skill in the art.
Expression and Production of CGV
The plasmids with the correct DNA sequence insertion were transformed into desired E. coli hosts. A single colony was picked and inoculated with LB media with appropriate selection antibiotics. CGV expression can be induced by IPTG or other inducers and purification is done by a modified protocol. The protocol including following steps:
To verify that insertion of heterologous peptide from one foreign protein or more foreign proteins can be realized in the present invention, in example 2, one 20-AA peptide from H1N1 virus HA (hemagglutinin) protein and another 20-AA peptide from Covid-19 virus Spike protein were linked to form a 40-AA insertion peptide. Then, the minor rib genes with heterologous peptide from two foreign proteins were inserted into the 14 gene gyp operon on the same plasmid or on two individual plasmid vectors. Transformation or co-transformation of the plasmid(s) into E. coli competent cells such that CGV particles carrying two or more heterologous peptides were brought on mass production.
To further validate protein expression of CGVs carrying various heterologous peptides, CGVs produced and isolated by procedures as described in example 1 were confirmed by Western Dot Blot.
CGV samples with various heterologous peptides were purified from the E. coli culture transformed with the corresponding plasmid constructs. The Western Dot Blot was done with rabbit anti-Covid-19 S protein as the primary antibody and goat anti-rabbit IgG-HRP as secondary antibody.
As shown in
The advantages of the present invention, chimeric gas vesicles (CGVs), over traditional GV and GVNP are numerous.
For example, previous attempts of direct genetic modification of GvpA in the conventional GV are unsuccessful due to the rigidity of GvpA in the GV. To date, no more than 5-AA heterologous peptide can be inserted at the C-terminus of GvpA without the destruction of GV. The CGV disclosed in the present invention overcomes this stability limitation and makes the CGVs possible for various applications. In GV research in halobacteria, the genetically modified GvpC of GVNP attaches to GV via protein-protein interaction, and is vulnerable to thermohaline fluctuations. This makes the GvpC easy to fall off from the GVNP, thus greatly reduces the possibility of using the conventional GVs for applications. In the CGVs, the heterologous peptide can be inserted or fused covalently with the truncated/native GvpA or its homolog to form the rib protein. As a part of the rib structure, the fall-off problem of the heterologous peptide present in the conventional GVs is eliminated. For industrial or commercial productions, the making of the CGVs can be accomplished in much shorter production cycle. In some instances, it can be produced within 2 days, which is drastically shorter than the production cycle of GVNPs in halobacteria or GVs in cyanobacteria. The CGVs are more stable than the conventional GVs. The CGVs produced in E. coli with gyp operon from P. megaterium are more stable than any other GVs previously known. The CGVs of the present invention have a higher “critical collapse pressure” than the conventional GVs. For storage, the CGVs in one of the embodiments maintain their integrity at room temperature for at least one month, and at 4° C. for at least six months, without any degradation. All these features of the CGVs of the present invention increases immensely the possibilities of its applications in the future.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
This application claims the benefit of provisional application Ser. No. 63/191,902, filed May 21, 2021.
| Number | Date | Country |
|---|---|---|
| WO-9720854 | Jun 1997 | WO |
| WO-2020146379 | Jul 2020 | WO |
| Entry |
|---|
| Felicitas Pfeifer, Distribution, formation and regulation of gas vesicles, Nature Reviews Microbiology, vol. 10, Oct. 2012 705. |
| Number | Date | Country | |
|---|---|---|---|
| 20220372085 A1 | Nov 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63191902 | May 2021 | US |
